List view / Grid view
12 November 2015 | By Victoria White
The data reveals antibiotic prescribing hotspots and interesting correlations against areas of deprivation. It also shows seasonal variation in antibiotic prescribing...
3 November 2015 | By Coulter Partners
Coulter Partners was delighted to partner with German diagnostics company Curetis AG on two strategic supervisory board appointments and congratulates them on their recent IPO launch...
In Issue #5 2015: Counterfeit Drugs, Regulatory Insight, Raman In-Depth Focus, PAT Series, Polymorphs, RMM In-Depth Focus, Particle Sizing, Freeze Drying, and much more...
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
14 October 2015 | By GE Healthcare
In this webinar, we discuss SPR fragment screening of wild type GPCRs enabled by sensitive biosensors and optimised membrane protein assays...
The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…
In Issue #4 2015: NGS, Informatics, Spray Drying, Excipients, Rapid Methods, NIR, PAT, Regulatory Insight and much more...
1 September 2015 | By Nick Jackson
As a precursor to the Phase III trial, this Phase IIb study will select the optimum dose, and is being conducted in Germany under the Therapy Allergens Ordinance (Therapieallergene-Verordnung)...
18 August 2015 | By Victoria White
NICE, the UK health watchdog, has published guidance to help doctors, nurses and pharmacists promote and monitor the sensible use of antibiotics...
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
31 July 2015 | By Victoria White
People in the UK have little awareness of what ‘antibiotic resistance’ means, according to new research commissioned by the Wellcome Trust...
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
15 July 2015 | By Victoria White
Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years...
In Issue #3 2015: Regulatory Insight, Microfluidics, PCR in-depth focus, Drug Delivery, Content Uniformity, HPLC, Microbiology in-depth focus, NMR, PAT and much more...
